Newly reported from ACC 2024 - Sara Saberi, MD: FOREST-HCM Data Demonstrates Long-Term Effects of Aficamten

Data from a 46-person cohort with 1 year of follow-up from the FOREST-HCM trial provides clinicians with further insight into the long-term effects of aficamten in patients with hypertrophic cardiomyopathy.

Presented at the American College of Cardiology 2024 (ACC.24) Annual Scientific Sessions, the latest data from the FOREST-HCM study details significant and sustained reductions in left ventricle outflow tract gradient (LVOT-G), and improvements in symptoms and cardiac biomarkers with use of aficamten, a cardiac myosin inhibitor from Cytokinetics.

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.